Sun Pharma settles patent dispute with US Celgene Corporation

IANSUpdated: Tuesday, June 22, 2021, 10:00 AM IST
article-image
Sun Pharma | PTI

Pharma major Sun Pharmaceutical Industries Ltd. on Tuesday said it along with one of its subsidiaries have reached an agreement with Celgene Corporation (Celgene) to resolve a patent litigation.

In a statement Sun Pharma said it along with its subsidiary has agreed with Celgene Corporation-a wholly-owned subsidiary of Bristol Myers Squibb, to resolve the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Revlimid (lenalidomide capsules) in the US.

As per the agreement, Celgene will grant Sun Pharma a license to Celgene's patents required to manufacture and sell (subject to USFDA approval) certain limited quantity of generic lenalidomide capsules in the US sometime after March 2022.

In addition, the license will also allow Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning January 31, 2026.

According to Sun Pharma, as a result of the settlement between Sun Pharma and Celgene under the US Hatch-Waxman Act, regarding the Revlimid patents, will be dismissed.

Additional details regarding the settlement are confidential. The agreement is subject to customary regulatory approvals, Sun Pharma said.

(If you have a story in and around Mumbai, you have our ears, be a citizen journalist and send us your story here. )

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Mumbai builder brothers up in arms: Vertical split in Kukreja family

Mumbai builder brothers up in arms: Vertical split in Kukreja family

IMF says Indian economy likely to slowdown to 6.1% in 2023 from 6.8% in 2022

IMF says Indian economy likely to slowdown to 6.1% in 2023 from 6.8% in 2022

BMC Budget on Feb 2: Health, infra and education to be in focus for fund allocation

BMC Budget on Feb 2: Health, infra and education to be in focus for fund allocation

Adani Group loses more than ₹5 lakh cr despite firefight against Hindenburg report

Adani Group loses more than ₹5 lakh cr despite firefight against Hindenburg report

Tech layoffs: CEO of US tech firm quotes Martin Luther King Jr in email firing people, gets trolled

Tech layoffs: CEO of US tech firm quotes Martin Luther King Jr in email firing people, gets trolled